syn023
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02956746)
Timeline
Indications
Studied for
- Communicable Diseases · Phase 3
- Disease Transmission, Infectious · Phase 1/Phase 2
- Immunization · Phase 1/Phase 2
- Mononegavirales Infections · Phase 3
- Rabies · Phase 3
- Rhabdoviridae Infections · Phase 3
- RNA Virus Infections · Phase 3
- Vaccines · Phase 1/Phase 2
- Virus Diseases · Phase 3
- Zoonoses · Phase 1/Phase 2
Mechanism of action
- Lyssavirus rabiesImmunity, passive
Lyssavirus rabies immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- syn023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04644484 | Phase 3 | Sep 23, 2020 | Clinchoice Inc, Government of China, Synermore Biologics Co., Ltd. |
| NCT03961555 | Phase 2 | Aug 31, 2019 | Synermore Biologics Co., Ltd. |
| NCT04495569 | Phase 1/Phase 2 (Phase 2) | Feb 26, 2019 | Synermore Biologics Co., Ltd. |
| NCT02956746 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | inVentiv, Synermore Biologics Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synermore Biologics Co., Ltd. | For profit | 4 | 4 | 2 | 2016 |
| Clinchoice Inc | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2020 |
| inVentiv | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1